Board Member
UNITED THERAPEUTICS Corp (UTHR)Equibles does not estimate personal net worth.
Get an email with a short summary when UNITED THERAPEUTICS Corp publishes a filing, an earnings call transcript or a press release.
Get UTHR alertsMartine Rothblatt is recorded as CEO and Board Member at UNITED THERAPEUTICS Corp (UTHR). The newest filing on record that lists Martine Rothblatt as Board Member at UNITED THERAPEUTICS Corp (UTHR) is dated April 29, 2022. UNITED THERAPEUTICS Corp reported in an 8-K filed June 29, 2026 that Martine Rothblatt was appointed Director, effective June 26, 2026. UNITED THERAPEUTICS Corp reported in an 8-K filed June 27, 2025 that Martine Rothblatt was appointed director, effective June 26, 2025. UNITED THERAPEUTICS Corp reported in an 8-K filed June 28, 2023 that Martine Rothblatt was appointed Director, effective June 26, 2023. The proxy statement of UNITED THERAPEUTICS Corp reports total compensation of $15,627,537 for Martine Rothblatt in fiscal 2019, including a base salary of $1,218,038. Disclosed compensation is on record for 3 fiscal years. Martine Rothblatt has spoken on 23 earnings calls and 1 other investor event across 1 company, most recently for UNITED THERAPEUTICS Corp on September 8, 2026. UNITED THERAPEUTICS Corp is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at UNITED THERAPEUTICS Corp includes Christopher Causey (Board Member), Christopher Patusky (Board Member), James Edgemond (Board Member) and 7 others.
“Election of directors, each to serve a term of one year: Nominee Votes For ... Martine Rothblatt 34,492,974 1,713,789 12,114 1,194,857”
“On June 26, 2025, the Company held its 2025 Annual Meeting of Shareholders.”
“United Therapeutics is right now at a major inflection point where we are rolling out 14 new products over the next few years that cumulatively will provide us, we believe, somewhere between $50 to $100 billion a year in pharma revenue, moving us to the very top tier of pharma companies.”
“We have slides available for reference, and I encourage you to review those at your leisure. I'm not going to speak directly to the slides. The first half of 2026 has been one of the most consequential periods in United Therapeutics history.”
“United Therapeutics is doing incredibly well—it is hard to imagine any other mid-cap biotech right now with prospects as good as ours. Here's what I mean.”
“It will reduce the number one side effect of dry powder inhalers, which is coughing, by up to 90% based on the human studies we've done so far. And we intend to file for its approval in PAH and ILD this year and commercially launch it next year.”
“United Therapeutics had a great quarter, helping more patients and earning more revenues than ever before. In addition, this past quarter, our pipeline made more progress than ever before.”
Start not stated–present
Last confirmed April 29, 2022
Drug Manufacturers - Specialty & Generic · Healthcare
CEO, Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2019 | UNITED THERAPEUTICS Corp (UTHR) | Chairman and Chief Executive Officer | $1,218,038 | $15,627,537 |
| 2018 | UNITED THERAPEUTICS Corp (UTHR) | Chairman and Chief Executive Officer | $1,208,447 | $16,036,300 |
| 2017 | UNITED THERAPEUTICS Corp (UTHR) | Chairman and Chief Executive Officer | $1,163,707 | $17,933,401 |
